Jubilant Pharmova Limited (IN:JUBLPHARMA)

:JUBLPHARMA

JUBLPHARMA

Jubilant Pharmova Limited

RESEARCH TOOLSreports

Jubilant Pharmova Limited (JUBLPHARMA) Price & Analysis

2 Followers

JUBLPHARMA Stock Chart & Stats

₹1056.10

₹15.25(1.49%)

At close: Jan 08 4:00 PM EST

₹1056.10

₹15.25(1.49%)

Day’s Range― - ―

52-Week Range₹783.75 - ₹1,250.00

Previous CloseN/A

Volume282.20K

Average Volume (3M)7.42K

Market Cap

₹142.04B

Enterprise Value₹163.67B

Total Cash (Recent Filing)₹6.23B

Total Debt (Recent Filing)₹28.83B

Price to Earnings (P/E)76.0

Beta1.06

Next Earnings

May 29, 2026

EPS Estimate

6.9

Next Dividend Ex-DateN/A

Dividend Yield0.46%

Share Statistics

EPS (TTM)5.00

Shares Outstanding159,281,140

10 Day Avg. Volume4,911

30 Day Avg. Volume7,424

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)2.33

Price to Sales (P/S)2.01

P/FCF Ratio-334.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,310.00

Price Target Upside24.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)45.5

Revenue Forecast (FY)₹91.10B

Bulls Say, Bears Say

Bulls Say

Diversified Business ModelMultiple, distinct revenue streams (CDMO services, radiopharma, allergy therapy, generics) reduce reliance on any single market or product. This diversification supports steadier cash flows, lowers customer concentration risk, and increases resilience to cyclical downturns over months to years.

Manufacturing & R&D CapabilitiesOn‑site manufacturing and R&D tailored to regulated markets create higher entry barriers and strengthen contract credibility. Capability to support development-to-commercial scale helps win long-term CDMO contracts and supports sticky customer relationships, sustaining revenue conversion over time.

Manageable Leverage And Improving ROEA moderate debt-to-equity ratio and roughly 50% equity base signal financial flexibility to fund operations or invest selectively. Improved ROE near mid-teens indicates better capital efficiency, supporting strategic investments without excessive balance-sheet stress in the medium term.

Bears Say

Negative Free Cash FlowSustained negative free cash flow driven by elevated capex constrains internal funding for debt reduction, dividends, or M&A. If capex intensity remains, the company may need external financing or slower reinvestment, reducing strategic optionality and increasing financing risk over months.

Earnings Per Share ContractionA sharp decline in EPS signals pressure on per-share profitability that can stem from margin compression, higher costs, or dilution. Persistent EPS contraction undermines shareholder returns and can limit retained earnings for reinvestment, weighing on long-term financial flexibility.

Low Net Profit MarginA modest net margin near 11.6% indicates limited ability to convert revenue into lasting profit. In competitive segments like generics and CDMO, margin pressure can persist and reduce cash generation, making funding of growth or absorbing shocks more difficult over the medium term.

Jubilant Pharmova Limited News

Jubilant Pharmova Creates Canadian Arm to Build Branded Generics Business

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an update. Jubilant Pharmova’s step-down subsidiary, Jubilant Generics Limited, has...

3M ago

Jubilant Pharmova Subsidiary to Appeal Rs 9.71 Crore GST Demand, Sees No Material Impact

An update from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) is now available. Jubilant Pharmova has disclosed that its...

4M ago

Jubilant Pharmova’s Subsidiary to Contest GST Adjudication Order

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an update. Jubilant Pharmova Limited has announced that its wholly...

4M ago

Jubilant Pharmova Appoints New CEO to Lead Therapeutics Subsidiary

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has provided an announcement. Jubilant Pharmova Limited has appointed Daniel J. O’Connor...

4M ago

Jubilant Pharmova Launches ‘Saksham Niveshak’ Campaign for Shareholders

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an announcement. Jubilant Pharmova Limited has launched the ‘Saksham Niveshak’...

5M ago

Jubilant Pharmova Releases Financial Results for Q2 2025

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an announcement. Jubilant Pharmova Limited has announced the publication of...

5M ago

Jubilant Pharmova Reports Unaudited Financial Results for September 2025

An announcement from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) is now available. Jubilant Pharmova Limited announced its unaudited...

5M ago

Jubilant Pharmova Grants Stock Options to Employees

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has provided an update. Jubilant Pharmova Limited’s Board of Directors has approved...

5M ago

Jubilant Pharmova Approves Stock Options to Enhance Employee Retention

The latest announcement is out from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ). Jubilant Pharmova Limited has announced the...

5M ago

Jubilant Pharmova Launches Initiative to Aid Shareholders in KYC Updates and Dividend Claims

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has shared an announcement. Jubilant Pharmova Limited has launched an initiative as...

6M ago

JUBLPHARMA FAQ

What was Jubilant Pharmova Limited’s price range in the past 12 months?

Jubilant Pharmova Limited lowest stock price was ₹783.75 and its highest was ₹1250.00 in the past 12 months.

What is Jubilant Pharmova Limited’s market cap?

Jubilant Pharmova Limited’s market cap is ₹142.04B.

When is Jubilant Pharmova Limited’s upcoming earnings report date?

Jubilant Pharmova Limited’s upcoming earnings report date is May 29, 2026 which is in 46 days.

How were Jubilant Pharmova Limited’s earnings last quarter?

Jubilant Pharmova Limited released its earnings results on Feb 06, 2026. The company reported ₹5 earnings per share for the quarter, missing the consensus estimate of ₹8.25 by -₹3.25.

Is Jubilant Pharmova Limited overvalued?

According to Wall Street analysts Jubilant Pharmova Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Jubilant Pharmova Limited pay dividends?

Jubilant Pharmova Limited pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Jubilant Pharmova Limited dividends here

What is Jubilant Pharmova Limited’s EPS estimate?

Jubilant Pharmova Limited’s EPS estimate is 6.9.

How many shares outstanding does Jubilant Pharmova Limited have?

Jubilant Pharmova Limited has 159,281,140 shares outstanding.

What happened to Jubilant Pharmova Limited’s price movement after its last earnings report?

Jubilant Pharmova Limited reported an EPS of ₹5 in its last earnings report, missing expectations of ₹8.25. Following the earnings report the stock price went down -4.177%.

Which hedge fund is a major shareholder of Jubilant Pharmova Limited?

Currently, no hedge funds are holding shares in IN:JUBLPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jubilant Pharmova Limited

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.

Jubilant Pharmova Limited (JUBLPHARMA) Earnings & Revenues

Historic Earnings Reports

JUBLPHARMA Stock 12 Month Forecast

Average Price Target

₹1,310.00

▲(24.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"815":"₹815","939":"₹939","1063":"₹1,063","1187":"₹1,187","1311":"₹1,311"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.31K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[815,939,1063,1187,1311],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Aug<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,816.45,854.4153846153847,892.3807692307693,930.3461538461539,968.3115384615385,1006.2769230769231,1044.2423076923078,1082.2076923076925,1120.173076923077,1158.1384615384616,1196.1038461538462,1234.0692307692307,1272.0346153846153,{"y":1310,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,816.45,854.4153846153847,892.3807692307693,930.3461538461539,968.3115384615385,1006.2769230769231,1044.2423076923078,1082.2076923076925,1120.173076923077,1158.1384615384616,1196.1038461538462,1234.0692307692307,1272.0346153846153,{"y":1310,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,816.45,854.4153846153847,892.3807692307693,930.3461538461539,968.3115384615385,1006.2769230769231,1044.2423076923078,1082.2076923076925,1120.173076923077,1158.1384615384616,1196.1038461538462,1234.0692307692307,1272.0346153846153,{"y":1310,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":898.61,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":910.51,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":893.48,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1164.62,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1164.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1192.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1160.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1039.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1113.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1055.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":957.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 151, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":848.8,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 259, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":816.45,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 289, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >